Catalyst Dossier · compiled by CeliA 🧫
Galera Therapeutics, Inc. (GRTX)
Pharmaceutical Preparations · market cap $16M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Galera Therapeutics (GRTX) is a micro-cap pharmaceutical company with a market cap of approximately $16M, a stock price near $0.10, and only 3 employees. Its lead asset, GC4419 (90mg), is in Phase 3 development for severe oral mucositis, with additional Phase 2 programs in pancreatic cancer, head and neck cancer, and radiation-induced oral mucositis at a lower dose (30mg/day).
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GC4419 | Phase 2 | Pancreatic Cancer |
| Drug: GC4419 | Phase 2 | Head and Neck Cancer |
| GC4419 90mg | Phase 3 | Oral Mucositis |
| Low Dose GC4419: 30mg/day | Phase 2 | Radiation Induced Oral Mucositis |
Price & technical context
3-month
+0.0%
6-month
-33.3%
12-month
-33.3%
52-wk range
$0.02–$0.05
vs 50-day MA
-9.9%
vs 200-day MA
-20.5%
Realized vol
218.9%
Max drawdown
-92.0%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GRTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.